Real-world data could meaningfully improve dementia treatment research by capturing how medications and interventions perform outside controlled clinical trials, where patients have multiple conditions, take other drugs, and live unpredictable lives. While clinical trials remain the gold standard for proving safety and efficacy, they enroll carefully selected participants who often don’t represent the broader population living with dementia—patients tend to be younger, healthier, and on fewer medications than those in typical memory care or home settings.
Researchers increasingly recognize that adding real-world evidence to trial data could reveal which treatments actually help the people most likely to receive them. Real-world data includes medical records, insurance claims, pharmacy data, patient registries, wearable device information, and outcomes tracked over months or years in regular clinical care. A person living with Alzheimer’s disease who participates in a clinical trial might take one medication in a closely monitored office setting, but that same person in actual practice may take that drug alongside medications for high blood pressure, heart disease, and depression—each interaction potentially affecting outcomes that trial protocols never tested.
Table of Contents
- What Is Real-World Data and How Differs It From Clinical Trial Evidence?
- The Limitations and Risks of Relying on Real-World Data Alone
- How Real-World Data Could Fill Specific Research Gaps
- Challenges in Designing Real-World Studies That Produce Trustworthy Results
- Data Privacy, Informed Consent, and Ethical Concerns
- Current Barriers to Building Large Real-World Dementia Datasets
- Emerging Approaches and Infrastructure for Real-World Evidence
What Is Real-World Data and How Differs It From Clinical Trial Evidence?
Clinical trials are designed to test whether a drug or treatment works under ideal conditions. Participants are screened carefully, excluded if they have other health problems, and seen regularly by researchers. This rigor produces clear, publishable results, but it creates a gap: the people enrolled in dementia trials often look different from the people who will ultimately take the drug. Someone with moderate dementia and three other chronic conditions may never be invited to join a trial—yet that person is exactly who will use the medication in a doctor’s office or assisted living facility.
Real-world data captures the messy reality of treatment. When a person picks up a prescription at a pharmacy, refills it (or doesn’t), and visits their doctor months later, that information—combined with pharmacy records, insurance claims, and clinical notes—creates a picture of how treatment actually unfolds. A patient might adjust their own dose because they felt better, skip doses because of cost, or stop taking the medication because of a side effect that never appeared in the trial. Real-world datasets, when large enough, can detect these patterns across thousands of people and reveal which treatments stick and why.
The Limitations and Risks of Relying on Real-World Data Alone
Real-world data cannot replace clinical trials, and confusing the two carries serious risks. Without the randomization and controls built into trials, it becomes nearly impossible to separate the effect of a drug from dozens of other factors—Did the person improve because of the medication, or because they started exercising, changed their diet, or simply had a better week? Insurance claims lack the detailed clinical assessments that trials collect, so researchers may not know severity of dementia, medication adherence, or whether a patient actually took the drug as prescribed. Privacy and data ownership present another barrier.
Extracting and combining medical records from different hospital systems, clinics, and insurers requires navigating complex regulations and patient consent rules that vary by region and institution. A researcher trying to build a real-world dataset for dementia treatment might need approval from multiple ethics boards and cooperation from institutions that rarely share data. Even when data can be pooled, the quality varies—one clinic may document outcomes meticulously while another records minimal information.
How Real-World Data Could Fill Specific Research Gaps
Real-world data shines when trials leave unanswered questions. Dementia medications often take months to show benefit, and some people respond better than others, but trials rarely track patients long enough or in large enough numbers to understand why. A real-world registry of people taking a particular Alzheimer’s drug could follow them for two, three, or five years and collect information about which combination of other medications works best, whether dose adjustments improve outcomes, or whether treatment helps more in early-stage versus advanced dementia.
Drug side effects represent another area where real-world data adds crucial information. A clinical trial of 1,500 people might not detect a rare side effect that occurs in one out of every 5,000 patients—but when a drug enters routine use and thousands of people take it, that side effect becomes visible in pharmacy data or insurance claims. For dementia treatments, which often target patients already managing multiple health problems, understanding real-world safety in broader populations could prevent harm and guide which patients should avoid certain medications.
Challenges in Designing Real-World Studies That Produce Trustworthy Results
Real-world research requires methods to handle the lack of randomization and control that clinical trials provide. When patients choose whether to take a medication, or when doctors select which patients receive treatment based on clinical judgment, those choices introduce bias. A person with more advanced dementia might be more likely to receive a particular treatment, making it impossible to know whether the drug itself caused the outcome or whether disease severity did.
Researchers have developed statistical techniques—propensity scoring, instrumental variables, and other methods—to attempt to correct for these biases, but none can fully replicate what randomization achieves. The tradeoff is this: real-world studies sacrifice some certainty about causation in exchange for seeing how treatment works in larger, more diverse, and more representative populations. This tradeoff makes sense for some research questions but not others. Understanding which side effects occur in the general population (where real-world data excels) is different from proving a new drug works better than placebo (where trials remain essential).
Data Privacy, Informed Consent, and Ethical Concerns
Using someone’s medical records for research, even with good intentions, raises legitimate privacy concerns. Patients living with dementia or their caregivers may not fully understand how their data could be used or who has access to it. Some people object to contributing their information to research, particularly if they don’t benefit directly or if they worry about genetic or diagnostic data being shared.
Regulations like HIPAA in the United States and GDPR in Europe set rules, but they don’t resolve the deeper question: Should medical records be used for research without explicit, ongoing consent? De-identification—removing names and other obvious identifiers—offers incomplete protection. Someone’s combination of age, sex, health conditions, and location can sometimes re-identify them, meaning that “anonymous” data might not be as private as it appears. For dementia research involving sensitive cognitive and behavioral information, this risk feels particularly acute. Researchers and institutions working with real-world data must invest in robust security and transparent policies about data access, but no system is completely secure.
Current Barriers to Building Large Real-World Dementia Datasets
Building a comprehensive real-world dataset for dementia research requires cooperation across hospitals, clinics, memory care facilities, and other healthcare providers—organizations that often use different electronic health records systems and rarely share data seamlessly. A person’s cognitive test scores from a neurologist’s office exist in one system, their prescriptions in a pharmacy’s database, and their hospital admission records elsewhere, with no easy way to connect them.
Insurance claims data provides one path forward, since insurance companies hold information about millions of patients across multiple providers. However, claims data lacks the clinical detail that researchers need—a claim shows that someone filled a prescription, but not whether they took it, how they responded, or whether they experienced side effects. Supplementing claims data with clinical records requires permission from individual patients and cooperation from healthcare providers, which slows the process significantly.
Emerging Approaches and Infrastructure for Real-World Evidence
Some healthcare systems and research networks have begun building integrated data platforms that allow researchers to access real-world information more easily. Academic medical centers and established disease registries—collections of data from patients willing to contribute information about their condition—provide models for how this infrastructure could work. When patients enroll in a registry, they agree to contribute their medical information for research, and researchers can then access de-identified data without negotiating with each individual hospital or clinic.
Dementia registries exist in various forms across different countries and research institutions, tracking outcomes for people with Alzheimer’s disease and other types of dementia. These registries have contributed to understanding disease progression, identifying which patients are at highest risk of rapid decline, and determining whether certain medications or lifestyle factors correlate with better or worse outcomes. A registry participant might provide blood samples, cognitive testing data, and medical history, allowing researchers to investigate questions that would be impossible to answer through clinical trials alone.
